Who owns BELITE BIO, INC (BLTE)? Elite investor 13F holders
3 tracked elite investors reported holding BELITE BIO, INC as of 2026-06-30, including Maverick Capital, Duquesne Family Office, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Maverick Capital | Belite Bio Inc Sponsored | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 61025949.00 USD | 396311.000000 | Shares | buy | Original filing |
| Duquesne Family Office | Belite Bio Inc Sponsored | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 16338000.00 USD | 106100.000000 | Shares | hold | Original filing |
| Renaissance Technologies LLC | Belite Bio Inc Sponsored | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 8586666.00 USD | 55763.000000 | Shares | add | Original filing |
| Tudor Investment | Belite Bio Inc Sponsored | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.